Open AccessSystemic Treatment Options in Hepatocellular Carcinoma
Author(s) -
Lorenza Rimassa,
Tiziana Pressiani,
Philippe Merle
Publication year - 2019
Publication title -
liver cancer
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000499765
Subject(s) - lenvatinib , regorafenib , sorafenib , cabozantinib , medicine , pembrolizumab , ramucirumab , nivolumab , hepatocellular carcinoma , oncology , clinical trial , atezolizumab , cancer , overall survival , immunotherapy , colorectal cancer
Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid changes are beginning to emerge in the treatment landscape of advanced HCC, with approvals of regorafenib, nivolu-mab, lenvatinib, pembrolizumab, and cabozantinib and positive phase II/III clinical trial results with other agents.